In summary, our report has demonstrated a novel observation that overexpression of RUNDC3A and SNAP25 modulates AKT protein stability to enhance tumour growth and chemoresistance in NECs, which suggests that this novel RUNDC3A/SNAP25/AKT axis may be a potential therapeutic target in patients with NECs. This evidence concerns the gene RUNDC3A and neoplasm.